Seven Eight Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Seven Eight Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30,297	Closed	-$2.56M	–	647
2018 Q4	$2.56M	Buy	+30,297	New	+$3.23M	0.14%	195
2018 Q3	–	Sell	-2,084	Closed	-$269K	–	641
2018 Q2	$269K	Buy	+2,084	New	+$233K	0.02%	418
2017 Q4	–	Sell	-2,405	Closed	-$204K	–	522
2017 Q3	$204K	Buy	+2,405	New	+$190K	0.02%	418

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Seven Eight Capital's LGND Position: Q1 2019 in Review

Seven Eight Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 30,297 shares — an estimated $2.56M sold.

Seven Eight Capital first reported a position in LGND in Q3 2017 and held it in 3 quarters. The position peaked at $2.56M in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Seven Eight Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Seven Eight Capital sold 30,297 Ligand Pharmaceuticals shares in Q1 2019, an estimated $2.56M.
Seven Eight Capital first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 3 quarters.
Seven Eight Capital's Ligand Pharmaceuticals position peaked at $2.56M in Q4 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Seven Eight Capital's 13F filing for Q1 2019, filed 15 May 2019.